143 related articles for article (PubMed ID: 1579624)
1. Pharmacokinetics of haloperidol and reduced haloperidol in Chinese schizophrenic patients after intravenous and oral administration of haloperidol.
Chang WH; Lam YW; Jann MW; Chen H
Psychopharmacology (Berl); 1992; 106(4):517-22. PubMed ID: 1579624
[TBL] [Abstract][Full Text] [Related]
2. Elimination half-life and bioavailability of haloperidol in schizophrenic patients.
Magliozzi JR; Hollister LE
J Clin Psychiatry; 1985 Jan; 46(1):20-1. PubMed ID: 3965439
[TBL] [Abstract][Full Text] [Related]
3. The bioavailability and pharmacokinetics of oral and depot intramuscular haloperidol in schizophrenic patients.
Nayak RK; Doose DR; Nair NP
J Clin Pharmacol; 1987 Feb; 27(2):144-50. PubMed ID: 3680566
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and bioavailability of benperidol in schizophrenic patients after intravenous and two different kinds of oral application.
Seiler W; Wetzel H; Hillert A; Schöllnhammer G; Langer M; Barlage U; Hiemke C
Psychopharmacology (Berl); 1994 Dec; 116(4):457-63. PubMed ID: 7701049
[TBL] [Abstract][Full Text] [Related]
5. Steady-state pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients: analysis of factors determining their concentrations in hair.
Uematsu T; Matsuno H; Sato H; Hirayama H; Hasegawa K; Nakashima M
J Pharm Sci; 1992 Oct; 81(10):1008-11. PubMed ID: 1432610
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of haloperidol in psychotic patients.
Cheng YF; Paalzow LK; Bondesson U; Ekblom B; Eriksson K; Eriksson SO; Lindberg A; Lindström L
Psychopharmacology (Berl); 1987; 91(4):410-4. PubMed ID: 3108922
[TBL] [Abstract][Full Text] [Related]
7. Haloperidol kinetics after oral and intravenous doses.
Holley FO; Magliozzi JR; Stanski DR; Lombrozo L; Hollister LE
Clin Pharmacol Ther; 1983 Apr; 33(4):477-84. PubMed ID: 6831826
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia.
Wiles DH; McCreadie RG; Whitehead A
Psychopharmacology (Berl); 1990; 101(2):274-81. PubMed ID: 2349370
[TBL] [Abstract][Full Text] [Related]
9. Effect of alosetron (a new 5-HT3 receptor antagonist) on the pharmacokinetics of haloperidol in schizophrenic patients.
Gupta SK; Kunka RL; Metz A; Lloyd T; Rudolph G; Perel JM
J Clin Pharmacol; 1995 Feb; 35(2):202-7. PubMed ID: 7751433
[TBL] [Abstract][Full Text] [Related]
10. Reversible metabolism of haloperidol and reduced haloperidol in Chinese schizophrenic patients.
Jann MW; Lam YW; Chang WH
Psychopharmacology (Berl); 1990; 101(1):107-11. PubMed ID: 2343070
[TBL] [Abstract][Full Text] [Related]
11. Prolonged haloperidol and reduced haloperidol plasma concentrations after decanoate withdrawal.
Chang WH; Lin SK; Juang DJ; Chen LC; Yang CH; Hu WH; Chien CP; Lam YW; Jann MW
Schizophr Res; 1993 Mar; 9(1):35-40. PubMed ID: 8461270
[TBL] [Abstract][Full Text] [Related]
12. Reduced haloperidol/haloperidol ratios after oral haloperidol and decanoate administration in schizophrenics.
Chang WH; Lin SK; Juang DJ; Chen LC; Yang CH; Hu WH; Chien CP; Lam YF; Jann MW
Prog Neuropsychopharmacol Biol Psychiatry; 1993 Jan; 17(1):105-12. PubMed ID: 8416597
[TBL] [Abstract][Full Text] [Related]
13. Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers.
Taylor TJ; Diringer K; Russell T; Venkatakrishnan K; Wilner K; Crownover PH; Benincosa LJ; Gibbs MA
Clin Pharmacokinet; 2006; 45(10):989-1001. PubMed ID: 16984212
[TBL] [Abstract][Full Text] [Related]
14. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
[TBL] [Abstract][Full Text] [Related]
15. The assessment and clinical implications of haloperidol acute-dose, steady-state, and withdrawal pharmacokinetics.
Khot V; DeVane CL; Korpi ER; Venable D; Bigelow LB; Wyatt RJ; Kirch DG
J Clin Psychopharmacol; 1993 Apr; 13(2):120-7. PubMed ID: 8463444
[TBL] [Abstract][Full Text] [Related]
16. A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy.
Wei FC; Jann MW; Lin HN; Piao-Chien C; Chang WH
J Clin Psychiatry; 1996 Jul; 57(7):298-302. PubMed ID: 8666571
[TBL] [Abstract][Full Text] [Related]
17. The pharmacokinetics and oral bioavailability studies of columbianetin in rats after oral and intravenous administration.
Luo Q; Wang CP; Li J; Ma WF; Bai Y; Ma L; Gao XM; Zhang BL; Chang YX
J Ethnopharmacol; 2013 Oct; 150(1):175-80. PubMed ID: 23994338
[TBL] [Abstract][Full Text] [Related]
18. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype.
Llerena A; Alm C; Dahl ML; Ekqvist B; Bertilsson L
Ther Drug Monit; 1992 Apr; 14(2):92-7. PubMed ID: 1585408
[TBL] [Abstract][Full Text] [Related]
19. Lack of pharmacokinetic interaction between buspirone and haloperidol in patients with schizophrenia.
Huang HF; Jann MW; Wei FC; Chang TP; Chen JS; Juang DJ; Lin SK; Lam YW; Chien CP; Chang WH
J Clin Pharmacol; 1996 Oct; 36(10):963-9. PubMed ID: 8930784
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of oral and intravenous omeprazole in patients with the Zollinger-Ellison syndrome.
Vinayek R; Amantea MA; Maton PN; Frucht H; Gardner JD; Jensen RT
Gastroenterology; 1991 Jul; 101(1):138-47. PubMed ID: 2044903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
